BridgeBio Pharma

BBIO

Market cap $14.7B

PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, announced today the pricing of $550 million aggregate principal amount of 0.75% convertible senior notes due 2033 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company granted the initial purchasers an option to purchase up to an additional $82.5 million aggregate principal amount of notes. The sale of the notes is expected to close on January 21, 2026, subject to customary closing conditions.

-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity

BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript

-  Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively

BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript

PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT.

PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Medicine and Public Health and investigator in PROPEL 3, the registrational Phase 3 study of infigratinib for children with achondroplasia. Dr. Legare also serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.

BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 and infigratinib. I expect 2026 to be another strong year with Attruby U.S. net sales in the $900-950 million range and I expect BridgeBio will reach non-GAAP profitability in Q4 2026. Infigratinib's phase 3 results are expected in the following weeks and represent the next important catalyst for the company.

PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 9 new employees in restricted stock units for an aggregate of 29,472 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam Pharmaceuticals.